General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1 — At a Glance
Most companies report a quarter where revenue is the big number and costs are the supporting cast. Suven Life Sciences reported ₹3.57 crore of revenue against ₹136.07 crore of expenses, which makes the revenue line less of a headline and more of a rounding difference.
Sales were up 90.9% year on year, from ₹1.87 crore. Operating profit was negative ₹132.50 crore against negative ₹50.75 crore a year earlier. Net loss was ₹127.61 crore versus ₹51.52 crore. EPS was negative ₹4.83.
None of this is an accident of one quarter. Suven Life Sciences is a clinical-stage biopharmaceutical company: it has no commercial molecule, so it has no product revenue, so every rupee it spends on research lands in the loss column with nothing to net it against. The P&L reads the way a lab notebook would if you gave it an accounting standard.
What it does have is money. Cash and bank stood at ₹337.46 crore at March 2026, up from ₹37.73 crore a year earlier, and financing activities brought in ₹756.78 crore during FY26. The company has received the entire ₹857.64 crore from its preferential warrant issue, of which ₹409.50 crore has been utilised.
Meanwhile the market assigns the whole thing a capitalisation of ₹9,674 crore, and the board announced that SUVN-502 has reached 95% enrolment in its global Phase 3 trial for agitation in Alzheimer’s dementia.
Somewhere in the space between ₹3.57 crore of revenue and ₹9,674 crore of market cap sits a pipeline. That pipeline is what the rest of this is about.
2 — Introduction
Suven Life Sciences is a Hyderabad-headquartered biopharmaceutical company engaged in drug discovery and development of New Chemical Entities in central nervous system disorders. Its lead molecules address cognitive impairment areas including amnesia, dementia, narcolepsy, Alzheimer’s and delirium. It operates through a wholly owned Delaware subsidiary, Suven Neurosciences Inc., established in 2015 to run clinical development.
The current shape of the company dates to 2020, when it demerged its CDMO business into Suven Pharmaceuticals Ltd, with shareholders allotted Suven Pharmaceuticals shares 1:1. What stayed behind was discovery and development. What left was the part that sold things. The revenue line tells that story with unusual clarity: ₹625.20 crore in FY18, ₹285.67 crore in FY19, ₹12.62 crore in FY20.
The last eighteen months have been dominated by capital raising. In May 2025 the board approved 6.40 crore convertible warrants to 23 allottees at an exercise price of ₹134 per share, approved by shareholders in June 2025. In March 2026 the company allotted 3.18 crore shares to Jasti Property at ₹134, for proceeds of ₹425.70 crore. In January 2026 it allotted 44.78 lakh shares at ₹134 for ₹60 crore. In July 2026 the board allotted a further 1.85 crore shares on warrant conversion for ₹248.84 crore, reappointed an independent director, and approved incorporation of a wholly owned subsidiary in Singapore.
On the clinical side, June 2026 was busy. A Data Safety Monitoring Board review of the Masupirdine Phase 3 was positive on 4 June with the trial continuing unchanged. SUVN-I6107 completed Phase 1 on 16 June. Ropanicant’s Phase 2b met its primary endpoint on 17 June, with a Phase 3 registrational study planned.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3 — Business Model: WTF Do They Even Do?
Suven Life Sciences develops molecules for the brain and, so far, sells none of them.
That isn’t a criticism, it’s the category. Fifteen molecules sit in the development and clinical pipeline — seven in development phases, eight having reached clinical phases. None has reached commercial stage, which is why none generates revenue. The business model is: spend money for a decade, run trials in humans, and find out.
The pipeline as disclosed this quarter reads like a tour of things the brain does badly. SUVN-502 (Masupirdine) is in global Phase 3 for agitation in Alzheimer’s dementia, at 95% enrolment, with enrolment completion targeted by end September 2026, last-patient-last-visit in Q1 calendar 2027, and results potentially in Q2 calendar 2027. SUVN-G3031 (Samelisant) entered global Phase 3 in April 2026 for excessive daytime sleepiness in narcolepsy. SUVN-911 (Ropanicant) completed Phase 2b in major depressive disorder. SUVN-D4010 (Usmarapride) has a Phase 2 proof-of-concept design being finalised for cognitive impairment in psychiatric disorder. SUVN-I6107 finished Phase 1 and is preparing for Phase 2.
Five molecules, five different stages, one revenue line of ₹3.57 crore.
The residual revenue comes from drug discovery and development support services provided to global pharma and biotech companies — in FY22, sales of services were 100% of revenues, with India at 53%, the USA around 38% and rest of world 9%. At ₹7.11 crore for all of FY26, this is not the engine; it is the thing that keeps the lights on while the engine is being built somewhere else.
The company reports a single business segment: Research & Development. No segment reporting is presented, because there is nothing
